Concepedia

Institution (Company)

Ipsen (United States)

HomepageWikipediaROR

Also Known As

Ipsen (United States)

421

Publications

12.6K

Citations

22

Authors

104

Concepts

About

Ipsen (United States) is a company institution in Cherry Valley, United States known for medicine, pharmacology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

21

64

3.2K

2

Health Sciences

6

9

897

3

Social Sciences

2

4

594

4

Public Health

1

5

90

5

Allergy

1

3

42

Ipsen (United States)

×

421

Publications

12.6K

Citations

YearCitations

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Robert J. Motzer, Paul B. Robbins, Thomas Powles,

Nature Medicine

2020

503

Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005

Lieven Annemans, Erik Spaepen, M. Gaskin,

Annals of the Rheumatic Diseases

2007

496

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

Robin Kate Kelley, Lorenza Rimassa, Ann‐Lii Cheng,

The Lancet Oncology

2022

494

Requirement of central ghrelin signaling for alcohol reward

Elisabet Jerlhag, Emil Egecioglu, Sara Landgren,

Proceedings of the National Academy of Sciences

2009

420

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

Zev A. Wainberg, Davide Melisi, Teresa Macarulla,

The Lancet

2023

374

NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors

Andrea Wang‐Gillam, Richard Hubner, Jens T. Siveke,

European Journal of Cancer

2019

299

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study

Martyn Caplin, Marianne Pavel, Jarosław B. Ćwikła,

Endocrine Related Cancer

2016

233

Chronic Treatment With a Melanocortin-4 Receptor Agonist Causes Weight Loss, Reduces Insulin Resistance, and Improves Cardiovascular Function in Diet-Induced Obese Rhesus Macaques

Paul Kievit, Heather Halem, Daniel L. Marks,

Diabetes

2012

223

The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity

Christina K. Baumgartner, Hakimeh Ebrahimi-Nik, Arvin Iracheta‐Vellve,

Nature

2023

145

Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial

Marianne Pavel, David J. Gross, Marta Benavent,

Endocrine Related Cancer

2018

135

Page 1